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Abstract
Objective: It is unknown whether there are differences in efficacy and safety be‐
tween quetiapine extended‐release, 300 mg/d (QUEXR300), and olanzapine,
5‐20 mg/d (OLA), for Japanese patients with bipolar depression.
Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan
of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate,
improvement on the Montgomery‐Åsberg Depression Rating Scale and 17‐item
Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of in‐
dividual adverse events. We calculated the standardized mean difference (SMD) and
the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichoto‐
mous data, respectively.
Results: There were no significant differences between QUEXR300 and OLA for any
of the efficacy outcomes. QUEXR300 was associated with a higher incidence of som‐
nolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated
with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and
blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300,
and a greater decrease in high‐density lipoprotein cholesterol levels (SMD = −0.408;
95% CrI = −0.785, −0.030) than QUEXR300.
Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk
of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long‐
term, head‐to‐head comparison study of QUEXR300 vs OLA for Japanese patients
with bipolar depression is needed to confirm the results of the current study.
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1 | I NTRO D U C TI O N

disorder. We reviewed phase 3 studies of each antipsychotic for bi‐
polar depression in Japan.

In Japan, olanzapine (OLA) and quetiapine extended‐release
1

(QUEXR) are approved for the treatment of bipolar depression. It

For OLA, a 6‐week, double‐blind, randomized, placebo‐con‐
trolled phase 3 trial (OLA, n = 343; placebo, n = 171) was conducted

is unknown, however, if one or the other antipsychotic is superior

in Japan, China, Taiwan, Korea, and the United States of America. 2

in terms of the risk‐benefit ratio for Japanese patients with this

This was a flexible‐dose study (5‐20 mg/d). Patients aged 18 to

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of
NeuropsychoPharmacology.
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64 years with bipolar I disorder who were acutely depressed were

compare the efficacy and safety of the two drugs in Japanese pa‐

recruited. Inclusion criteria were as follows: a depressive episode

tients with bipolar depression (Appendix S1).

for ≤ 90 days at the time of randomization, a total score ≥ 18 on the
17‐item Hamilton Rating Scale for Depression (HAMD‐17), 3 and a
history of ≥ 1 manic or mixed episode in the previous 6 years, but
not currently having a manic episode (Young Mania Rating Scale

2 | M E TH O DS

[YMRS]4 total score ≤ 8 at randomization). The primary outcome

2.1 | PICO

of the study was the change from mean baseline to study endpoint

Patients with bipolar depression who were not being treated with

in the Montgomery‐Åsberg Depression Rating Scale (MADRS)5
score. Although OLA was superior to placebo in terms of im‐
proved MADRS score and response (defined as a ≥ 50% reduction
in MADRS at endpoint) rate, there was no significant difference
in remission (defined as a MADRS total score ≤ 12) rate between
the groups. Compared with placebo, OLA was associated with a
higher incidence of somnolence, sedation, significant weight gain
(≥7% body weight), and increased appetite. Patients taking OLA
also had significantly increased total cholesterol, triglyceride, and
low‐density lipoprotein (LDL) cholesterol levels. An analysis was
also conducted of the Japanese subpopulation in this study (OLA,
n = 104; placebo, n = 52).6 Although OLA was superior to placebo in
terms of an improved MADRS score, there were no significant dif‐
ferences in rates of response (same definition as the primary anal‐
ysis) or remission (same definition as the primary analysis) between
OLA and placebo. In the Japanese subgroup, compared with pla‐
cebo, OLA was associated with a higher incidence of somnolence
and significant weight gain (≥7% body weight) and significantly in‐
creased total cholesterol, triglyceride, and LDL cholesterol levels,

any mood stabilizers or antipsychotics at baseline were eligible. The
intervention groups were given OLA or QUEXR300, and the control
group was given placebo. The outcomes were efficacy and safety/
tolerability (detailed information in the following section).

2.2 | Data synthesis
Two authors (T.K. and Y.M.) extracted data from the articles and
entered it into a spreadsheet. The primary outcome of remission
was defined as a MADRS score ≤12. The secondary outcomes in‐
cluded response (≥50% reduction in the MADRS score from baseline
to endpoint) rate, an improvement in MADRS and HAMD‐17 total
scores from baseline, all‐cause discontinuation, discontinuation due
to adverse events, and individual adverse events. Only intention‐to‐
treat population data were used in the analysis. For the OLA study,
we used only data from the Japanese patients. The algebraic signs
of the values of HDL cholesterol were reversed, as a decrease in the
HDL cholesterol level indicates a worse response.

along with significantly decreased high‐density lipoprotein (HDL)
cholesterol levels. Thus, there were differences in some of the ef‐
ficacy and safety outcomes between the primary and the Japanese
subpopulation analyses.
An 8‐week, double‐blind, randomized, placebo‐controlled
phase 3 trial of QUEXR was conducted in Japan.7 This was a
fixed‐dose study comparing QUEXR at 300 mg/d (QUEXR300,
n = 179), at 150 mg/d (QUEXR150, n = 74), and placebo (n = 177).
The investigators discontinued recruitment to the QUEXR150
arm because of difficulty in finding enough patients. Therefore,
efficacy outcomes for QUEXR150 were not reported. Patients 20

2.3 | Statistical analysis
A Bayesian analysis was conducted using the GeMTC package in R
Statistics software.8 We used a fixed effects model for this study
because a random effects model might be too conservative for this
small a Bayesian analysis. We calculated the standardized mean dif‐
ference (SMD) and the risk ratio (RR) and 95% credible interval (95%
CrI) for continuous and dichotomous data, respectively. The number
of burn‐in iterations, the number of interface iterations, and thinning
factor were set at 5000, 20 000, and 10, respectively.

to 64 years old with bipolar I disorder or bipolar II disorder who
were acutely depressed were recruited. Inclusion criteria were a
HAMD‐17 total score ≥20, a HAMD‐17 depressed mood score
≥2 points, a YMRS total score <13, and <9 mood episodes within
12 months prior to informed consent. The primary outcome of the
study was the mean change from baseline to study endpoint in
the MADRS score. QUEXR300 was superior to placebo in improv‐
ing the MADRS score and rates of response (same definition as
the OLA study) and remission (same definition as the OLA study).

3 | R E S U LT S
3.1 | Study characteristics
The two studies were double‐blind, randomized, placebo‐controlled
trials sponsored by pharmaceutical companies and were published
in English. The methodological quality of both studies was high as
assessed with the Cochrane Risk of Bias Tool.

QUEXR300 was associated with a higher incidence of somnolence
and dry mouth than placebo.
No head‐to‐head study of QUEXR300 vs OLA has been con‐

3.2 | Results of Bayesian analysis

ducted to assess efficacy and safety among Japanese patients with

There were no significant differences between QUEXR300 and

bipolar depression. Therefore, we conducted a Bayesian analysis

OLA in any of the efficacy outcomes (Table 1). Although QUEXR300

of data from both the Japan OLA and QUEXR phase 3 studies to

was associated with a higher incidence of somnolence than OLA
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Bayesian analysis: QUEXR300 vs OLA
RR (95% CrI)a

study might influence the results of our study. However, we did not
examine whether those clinical factors were associated with the re‐
sults of the study (for example, somnolence) because the number

Remission rate

0.786 (0.478, 1.257)

Response rate

1.109 (0.769, 1.577)

All‐cause discontinuation

1.044 (0.476, 2.276)

bility of sponsorship bias should be considered when interpreting

Discontinuation due to adverse events

1.089 (0.277, 3.654)

our results.10 Thirdly, this study did not evaluate several common

Significant weight gain (≥7% body
weight)

0.251 (0.009, 2.573)

adverse events such as extrapyramidal symptoms, constipation, or

Somnolence

5.517 (1.563, 19.787)

both trials had a short duration. A large scale, long‐term, head‐to‐

SMD (95% CrI)b

head comparison of QUEXR300 vs OLA for Japanese patients with

of studies and of patients analyzed was small. Secondly, both stud‐
ies included in the analysis were industry sponsored, so the possi‐

dry mouth because there were insufficient data for analysis. Finally,

bipolar depression is needed to confirm the results of the current

MADRS

0.189 (−0.245, 0.626)

HAMD‐17

0.283 (−0.114, 0.681)

Body weight

−0.488 (−0.881, −0.089)

Fasting blood sugar

−0.114 (−0.517, 0.291)

AC K N OW L E D G M E N T S

Serum triglycerides

−0.011 (−0.407, 0.390)

We thank Mr Shinji Yamamoto [Kyowa Pharmaceutical Industry Co.,

Serum total cholesterol

−0.086 (−0.483, 0.314)

Ltd. (Osaka, Japan 〒530‐0005)] and Mr Masanobu Tatsumi [Kyowa

Serum HDL cholesterol

−0.408 (−0.785, −0.030)

Pharmaceutical Industry Co., Ltd. (Osaka, Japan 〒530‐0005)] for

Serum LDL cholesterol

−0.172 (−0.575, 0.230)

providing information for Murasaki's study.

Blood prolactin

−0.642 (−1.073, −0.213)

Abbreviations: 95% CrI, 95% credible interval; HAMD‐17, 17‐item
Hamilton Rating Scale for Depression; HDL cholesterol, high‐density
lipoprotein cholesterol; LDL cholesterol, low‐density lipoprotein choles‐
terol; MADRS, Montgomery‐Åsberg Depression Rating Scale; RR, risk
ratio; SMD, standardized mean differences.
a
RR < 1 favors QUEXR300; RR > 1 favors OLA.
b
Negative SMD values favor QUEXR300; positive SMD values favor
OLA.

study.
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OLA in terms of efficacy and safety outcomes for Japanese patients
with bipolar depression. We did not detect any differences in ef‐
ficacy between the two drugs. However, OLA had a greater risk

AU T H O R C O N T R I B U T I O N S

than QUEXR300 of weight gain and decreased HDL cholesterol
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sponsibility for the integrity of the data and the accuracy of the data

had a greater risk of somnolence than OLA. A recent systematic re‐
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data: Kishi. Statistical analysis: Kishi and Ikuta. Acquisition of data:

evening rather than at bedtime, the incidence of somnolence would

Kishi and Matsuda. Drafting of the manuscript: All authors. Study

decrease.9

supervision: Iwata.

The study has several limitations. First, the differences in the
characteristics of the patients (diagnosis: OLA = bipolar I disorder,
QUEXR300 = bipolar I disorder or bipolar II disorder) and the stud‐

DATA AVA I L A B I L I T Y

ies (duration of study [6 weeks study vs 8 weeks study] and dos‐

Data used for the current study are reported in the Katagiri et al6

ing effect [flexible‐dose study vs fixed‐dose study]) included in this

and Murasaki et al7.
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